[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![WallStSai Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::90807052.png) S A I ™️ [@WallStSai](/creator/twitter/WallStSai) on x 7066 followers
Created: 2025-07-14 01:52:07 UTC

$XBI The pharmaceutical industry is facing some of its steepest patent cliffs to date. 

$MRK $PFE $BMY $AMGN $GILD $LLY $AZN $NVS $JNJ $SNY $ABBV 

Drugs worth about $180bn of revenue a year are going off patent in 2027 and 2028, according to research firm Evaluate Pharma, representing almost XX per cent of the global market. 

Big Pharma is looking for biotechs with drugs that could come on to the market soon and sell in their billions.

While patent cliffs are visible years ahead, investors are often not that “far sighted” and can be “surprised” when they come, says Tim Opler, a managing director in Stifel’s global healthcare group. “The pressure on pharma to find some way to augment the revenues is extremely high.”

Source:


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944575606416715921/c:line.svg)

**Related Topics**
[manat](/topic/manat)
[amgn](/topic/amgn)
[pfe](/topic/pfe)
[cent](/topic/cent)
[$180bn](/topic/$180bn)
[drugs](/topic/drugs)
[$sny](/topic/$sny)
[$jnj](/topic/$jnj)

[Post Link](https://x.com/WallStSai/status/1944575606416715921)